SANTARIS PHARMA A/S - Denmark 

Ranking results:

Past rankings:

2012
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
Networking Rank (Reputation):> 1000

Ranking timeline:

Project Participation Performance(2012-01-01 - 2024-12-31 ):

Total Project Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:

Leadership:

Total number of projects: 2
As coordinator: 0
As participant: 2
Sole participant: 0
Coordinator / Participant Ratio: 0*

*Ratio includes only projects with > 2 partners

Summary:

Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2013 0 11.879.878 1.537.290 2
*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:

Institution:Projects [No]:
ALTA RICERCA E SVILUPPO IN BIOTECNOLOGIE SRL ALTA2
KAROLINSKA INSTITUTE2
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD2
BERING LIMITED1
BIOMEDICAL RESEARCH FOUNDATION ACADEMY OF ATHENS1
CENIX BIOSCIENCE1
GENOWAY1
INSTITUT PASTEUR1
LUNDS UNIVERSITET1
PIRKANMAA HOSPITAL DISTRICT1
SYDDANSK UNIVERSITET1
UNIVERSITA DEGLI STUDI DI GENOVA1
UNIVERSITAIR MEDISCH CENTRUM UTRECHT1
UNIVERSITE DE GENEVE1
UNIVERSITY COLLEGE LONDON1
WEIZMANN INSTITUTE OF SCIENCE1
ZORA BIOSCIENCES1

Constancy:

Total number of partners: 20
Partner loyalty:
Frequent Partner: (> 2 projects): 0
Rare Partner: 20
Frequent / Rare Partner Ratio: 0

Project overview:

Start dateProjectacronymrolefundingpartners
2013-09-01Targeting and exploiting B cell functions for treatment in cardiovascular disease ATHERO-B-CELLparticipant5.892.17811
2013-09-01Targeting novel lipid pathways for treatment of cardiovascular disease ATHERO-FLUXparticipant5.987.70011